Germany’s G-BA, the body in charge of drug pricing and reimbursement, has for the first time used new powers to oblige companies to generate post-launch evidence on their products.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?